Evidence map›Paper›PMID 36875796›Full record

ArticleBiochemistry and biophysics reports2023

Producing amyloid fibrils in vitro: A tool for studying AL amyloidosis.

Daria V Sizova, Steve Raiker, Deaneira Lakheram, Vishwanatha Rao, Andrew Proffitt, Yazen Jmeian, Walter Voegtli, Melissa Batonick

Open access · goldAbstract read
In one paragraph

Article in Biochemistry and biophysics reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Daria V SizovaAlexion AstraZeneca Rare Disease, 100 College Street, New Haven, CT, 06510, USA.
Steve RaikerAlexion AstraZeneca Rare Disease, 100 College Street, New Haven, CT, 06510, USA.
Deaneira LakheramAlexion AstraZeneca Rare Disease, 100 College Street, New Haven, CT, 06510, USA.
Vishwanatha RaoAlexion AstraZeneca Rare Disease, 100 College Street, New Haven, CT, 06510, USA.
Andrew ProffittAlexion AstraZeneca Rare Disease, 100 College Street, New Haven, CT, 06510, USA.
Yazen JmeianAlexion AstraZeneca Rare Disease, 100 College Street, New Haven, CT, 06510, USA.
Walter VoegtliAlexion AstraZeneca Rare Disease, 100 College Street, New Haven, CT, 06510, USA.
Melissa BatonickAlexion AstraZeneca Rare Disease, 100 College Street, New Haven, CT, 06510, USA.
Alexion Pharma (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyloid light-chain (AL) amyloidosis is the second most common form of systemic amyloidosis which is characterized by a high level of mortality and no effective treatment to remove fibril deposition. This disorder is caused by malfunctioning of B-cells resulting in production of abnormal protein fibrils composed of immunoglobulin light chain fragments that tend to deposit on various organs and tissues. AL amyloidosis is set apart from other forms of amyloidosis in that no specific sequences have been identified in the immunoglobulin light chains that are amyloid fibril formation causative and patient specific. This unusual feature hinders the therapeutic progress and requires either direct access to patient samples (which is not always possible) or a source of in vitro produced fibrils. While isolated reports of successful AL amyloid fibril formation from various patient-specific protein sequences can be found in literature, no systematic research on this topic was performed since 1999. In the present study we have developed a generalized approach to in vitro fibril production from various types of previously reported [[1], [2], [3]] amyloidogenic immunoglobulin light chains and their fragments. We describe the procedure from selection and generation of starting material, through finding of optimal assay conditions, to applying a panel of methods to confirm successful fibril formation. Procedure details are discussed in the light of the most recent findings and theories on amyloid fibril formation. The reported protocol produces high quality AL amyloid fibrils that can subsequently be used in the development of the much-needed amyloid-targeting diagnostic and therapeutic approaches.

Indexed as

AL amyloidosisAmyloid fibril testsAmyloidogenesis in vitroAmyloidogenic light chainsFibril formation protocol

Identifiers

PMID36875796
PMCPMC9982448
OpenAlexW4321785147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.